Replies to post #386868 on NorthWest Biotherapeutics Inc (NWBO)

[X Master]

Did CVM fail?

10:27 AM EDT, 06/28/2021 (MT Newswires) -- Cel-Sci (CVM) said Monday that its Multikine immunotherapy yielded significant overall survival benefit in patients with advanced and primary squamous cell carcinoma of the head and neck.

Data obtained from a phase 3 trial showed that patients had an overall survival benefit of 14.1% with overall survival of 62.7% at five years for those receiving the Multikine treatment regimen followed by surgery and radiotherapy therapy, but not chemotherapy, as part of their standard of care. No safety issues were observed for Multikine in the treated population, according to the company.

CEL-SCI said it plans to seek US Food and Drug Administration approval for Multikine based on the immunotherapy's demonstrated significant overall survival benefit and favorable safety profile.

Price: 18.00, Change: -7.08, Percent Change: -28.23

[cfoofme]

CVM only “failed” in its combination with chemo.